Safety and Antidepressant Effects of Rellidep in Major Depressive Disorder

Phase 2

Completed

• Conditions: Depression

• Registration Number: NCT00446719
• Lead Sponsor: Mount Sinai Hospital, Canada

Brief Summary

The investigators hypothesize that Rellidep will be effective in improving the symptoms of major depression. The available evidence strongly suggests that Rellidep contains a mood altering ingredient or ingredients. This open-label, non-randomized study sets out to validate its potential antidepressant activity.The study will include secondary aims of evaluating the effect of Rellidep on reducing symptoms of anxiety, a common symptom associated symptom of depression and improving quality of life.

About twenty-five patients with major depressive disorder will be assigned to open-label Rellidep (2000 mg/day) for a period of 8 weeks. All patients will be assessed by various measures of global improvement, depression, quality of life, sexual experience, anxiety and measures of side effects as well as standard laboratory tests.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2007-03-09
• Study First Submitted QC: 2007-03-12
• Study First Posted: 2007-03-13
• Study Start: 2007-08
• Primary Completion: 2008-12
• Study Completion: 2008-12
• Status Verified: 2011-01
• Last Update Submitted: 2011-01-04
• Last Update Posted: 2011-01-05

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 23

Inclusion Criteria

• Signed written informed consent obtained.
• Males/Females 20-65 years of age who require a new or a new change in their medication treatment for diagnosed major depression.
• A clinical diagnosis fulfilling DSM-IVTR criteria for Major Depressive Disorder, single episode or recurrent.
• 17-Item Hamilton Depression Rating Scale (HAMD 17-item) total score at baseline of 18 or higher

Exclusion Criteria

• Clinical diagnosis of depression other than DSM-IVTR Major Depressive Disorder (single episode/recurrent, e.g. chronic depression and/or refractory depression are excluded).
• Judged to be at significant risk for suicide or having a history suggesting significant current potential for self harm.
• Antidepressant medication (other than the index antidepressant).
• Women who are pregnant or breast-feeding or intending to become pregnant in the next 12 months.
• Clinically significant organ system diseases, e.g. cardiovascular, hepatic, renal, endocrine, gastrointestinal, metabolic, or other systemic diseases.
• Course of electroconvulsive therapy (ECT) during the observational period.
• Suffer from a major neurological condition (i.e., Parkinson's disease, Huntington's disease), cerebrovascular disease (i.e., stroke), metabolic conditions (i.e., Vitamin B12 deficiency), autoimmune conditions (i.e., systematic lupus erythematosus), viral or other infections (i.e., hepatitis, mononucleosis, human immunodeficiency), and cancer.
• Current diagnosis of Schizophrenia or other psychotic disorders (including Schizophreniform Disorder, Schizoaffective Disorder, Delusional Disorder, brief psychotic disorders, psychotic disorder due to general medical condition, substance induced psychotic, psychotic disorder not otherwise specified) as defined in the DSM-IV.
• (Sub) clinical hypo/hyper thyroidism (e.g. elevated TSH).

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
50% improvement on Hamilton Depression Rating Scale-17 at 8 weeks	8 weeks

Secondary Outcome Measures

Name	Time	Method
UKU	8 weeks
Hamilton rating scale for Anxiety (HAM-A)at 8 weeks	8 weeks
Clinical Global Impression-Severity and Improvement	8 weeks
Beck Depression Inventory Scale (BDI) a t 8 weeks	8 weeks
Montgomery Asberg Depression Rating Scale (MADRS) at 8 weeks	8 weeks
Medical Outcomes Study Short-Form 36 (SF-36)at 8 weeks	8 weeks

Trial Locations

Locations (1)

Mount Sinai Hospital; 🇨🇦 Toronto, Ontario, Canada